| 000 | 01841 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513074953.0 | ||
| 264 | 0 | _c19930915 | |
| 008 | 199309s 0 0 eng d | ||
| 022 | _a1042-8194 | ||
| 024 | 7 |
_a10.3109/10428199309148532 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEstey, E | |
| 245 | 0 | 0 |
_aFludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _cMar 1993 |
||
| 300 |
_a343-50 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aBone Marrow Diseases _xchemically induced |
| 650 | 0 | 4 | _aBone Marrow Transplantation |
| 650 | 0 | 4 |
_aColitis _xchemically induced |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aConjunctivitis _xchemically induced |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPancreatitis _xchemically induced |
| 650 | 0 | 4 |
_aPeripheral Nervous System Diseases _xchemically induced |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVidarabine _xadministration & dosage |
| 700 | 1 | _aPlunkett, W | |
| 700 | 1 | _aGandhi, V | |
| 700 | 1 | _aRios, M B | |
| 700 | 1 | _aKantarjian, H | |
| 700 | 1 | _aKeating, M J | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 9 _gno. 4-5 _gp. 343-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/10428199309148532 _zAvailable from publisher's website |
| 999 |
_c8393440 _d8393440 |
||